[A19-75] Dupilumab (atopic dermatitis in adolescents) - Benefit assessment according to §35a Social Code Book V

Last updated 02.12.2019

Project no.:
A19-75

Commission:
Commission awarded on 29.08.2019 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Skin and hair

Indication:

Adolescents aged 12 years and older with moderate to severe atopic dermatitis who are candidates for systemic therapy

Result of dossier assessment:

Negative effect in the outcome category of side effects does not call into question positive effects in morbidity and health-related quality of life; indication of non-quantifiable added benefit

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Federal Joint Committee (G-BA)

2020-02-20 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.